4398 - Duodopa (Answered)

Mr Virendra Sharma
To ask the Secretary of State for Health, what progress NHS England has made in its review of the draft clinical commissioning policy for Duodopa; and how the views of clinicians and those affected by Parkinson's disease have been taken into account during that review.

George Freeman

On 24 March 2015, NHS England launched a 30 day public consultation on a proposed number of new products for specialised services, including a clinical commissioning policy for co-careldopa intestinal gel (Duodopa).

There has already been extensive engagement on these national specifications and policies, as they have been developed with the support and input of lead clinicians and patient and public representatives. This approach has helped ensure that the views of key stakeholders have informed and influenced the development of the policies and specifications so far.

The consultation was open to anyone who wished to respond. Further information about the consultation, together with a copy of the draft policy, can be found on NHS England’s website and accessed via the following link: